The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,744.50
Bid: 1,744.00
Ask: 1,744.50
Change: -30.00 (-1.69%)
Spread: 0.50 (0.029%)
Open: 1,776.50
High: 1,776.50
Low: 1,743.50
Prev. Close: 1,774.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK Annual Report 2023 on Form 20-F

5 Mar 2024 17:24

RNS Number : 7075F
GSK PLC
05 March 2024
 

Issued: 5 March 2024, London UK

 

GSK plc 2023 Annual Report on Form 20-F

 

 

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GSK plc ("GSK") announces that on 5 March 2024 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2023. GSK's 2023 Annual Report on Form 20-F is available online at GSK's website at www.gsk.com/corporatereporting and also online at www.sec.gov.

A hard copy version of the GSK 2023 Annual Report, together with the Notice of Annual General Meeting, will be available on or about 25 March 2024.

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2023, free of charge, by either:

 

(i)

writing to Equiniti Limited, our registrars in the UK, at the following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on +44 (0)371 384 2991 (please use the area code if calling from outside the UK);

 

(ii)

writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the following address: EQ Shareowner Services, P.O. Box 64504, St. Paul, MN 55164-0504, or by telephone on +1 877 353 1154 (US toll free) or +1 651 453 2128 (outside the US); or

 

(iii)

contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).

 

 

 

About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

 

Victoria WhyteCompany Secretary5 March 2024

 

Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2023.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSQKPBBOBKDKNK
Date   Source Headline
16th Apr 20201:49 pmRNSDirector/PDMR Shareholding
14th Apr 20204:35 pmRNSDirector/PDMR Shareholding
14th Apr 20204:31 pmRNSDirector/PDMR Shareholding
14th Apr 20203:09 pmRNSDirector/PDMR Shareholding
14th Apr 202012:00 pmRNSSanofi and GSK collaboration to fight COVID-19
9th Apr 202011:52 amRNSAGM - Change of Arrangements
6th Apr 20201:00 pmRNSGSK and Vir Biotechnology enter collaboration
1st Apr 202012:57 pmRNSGSK completes divestment of Horlicks
1st Apr 202011:11 amRNSTotal Voting Rights
30th Mar 20204:06 pmRNSConsumer Healthcare product sales category changes
25th Mar 20204:42 pmRNSSecond Price Monitoring Extn
25th Mar 20204:37 pmRNSPrice Monitoring Extension
24th Mar 20204:40 pmRNSSecond Price Monitoring Extn
24th Mar 20204:35 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSPublication of AGM Notice
20th Mar 20202:00 pmRNSDirectorate Change
18th Mar 202012:20 pmRNSDirector/PDMR Shareholding
13th Mar 20205:24 pmRNSEMTN Prospectus Supplement Update
11th Mar 20205:00 pmRNSDirector/PDMR Shareholding
9th Mar 20204:15 pmRNSDirector/PDMR Shareholding
9th Mar 20207:00 amRNSPublication of GSK 2019 Form 20-F
4th Mar 20202:53 pmRNSAnnual Financial Report
2nd Mar 202011:00 amRNSTotal Voting Rights
21st Feb 20201:00 pmRNSDirector/PDMR Shareholding
20th Feb 20203:30 pmRNSDirector/PDMR Shareholding
20th Feb 20202:00 pmRNSDirector/PDMR Shareholding
20th Feb 20202:00 pmRNSDirector/PDMR Shareholding
19th Feb 20205:25 pmRNSDirector/PDMR Shareholding
19th Feb 20204:35 pmRNSDirector/PDMR Shareholding
19th Feb 20204:28 pmRNSDirector/PDMR Shareholding
19th Feb 20204:24 pmRNSDirector/PDMR Shareholding
19th Feb 20204:17 pmRNSDirector/PDMR Shareholding
12th Feb 20205:05 pmRNSDirector/PDMR Shareholding
11th Feb 20202:15 pmRNSDirector/PDMR Shareholding
11th Feb 20207:00 amRNSTransfer of Treasury Shares
6th Feb 20204:00 pmRNSDirector/PDMR Shareholding
5th Feb 20204:15 pmRNSDirector/PDMR Shareholding
5th Feb 202012:00 pmRNSFinal Results
3rd Feb 20203:15 pmRNSGSK publishes provisional 2020 Dividend Dates
3rd Feb 20209:30 amRNSTotal Voting Rights
15th Jan 20207:00 amRNSDirector/PDMR Shareholding
14th Jan 20204:46 pmRNSDirector/PDMR Shareholding
14th Jan 20204:01 pmRNSDirector/PDMR Shareholding
13th Jan 20206:00 pmRNSDirector/PDMR Shareholding
13th Jan 202011:41 amRNSDirector/PDMR Shareholding
13th Jan 202011:01 amRNSDirector/PDMR Shareholding
13th Jan 202010:34 amRNSDirector/PDMR Shareholding
8th Jan 20204:30 pmRNSGSK publishes provisional 2020 Dividend Dates
8th Jan 20203:11 pmRNSGSK publishes 2020 Dividend Dates
8th Jan 20202:37 pmRNSGSK Announces addition to Corporate Executive Team

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.